Featured Research

from universities, journals, and other organizations

Hello Wearable Kidney, Goodbye Dialysis Machine

Date:
August 21, 2009
Source:
American Society of Nephrology
Summary:
Researchers are developing a Wearable Artificial Kidney for dialysis patients.

Researchers are developing a Wearable Artificial Kidney for dialysis patients, reports an upcoming paper in the Clinical Journal of the American Society of Nephrology (CJASN). "Our vision of a technological breakthrough has materialized in the form of a Wearable Artificial Kidney, which provides continuous dialysis 24 hours a day, seven days a week," comments Victor Gura, MD (David Geffen School of Medicine at UCLA).

The device—essentially a miniaturized dialysis machine, worn as a belt—weighs about 10 pounds and is powered by two nine-volt batteries. Because patients don't need to be hooked up to a full-size dialysis machine, they are free to walk, work, or sleep while undergoing continuous, gentle dialysis that more closely approximates normal kidney function.

Such a device could lead to a "paradigm change" in the treatment of dialysis patients. Despite enduring long hours on dialysis every week—with major limitations in activities, diet, and other areas of life—dialysis patients face high rates of hospitalization and death. The U.S. dialysis population currently exceeds 400,000, with costs of over $30 billion per year. "We believe that the Wearable Artificial Kidney will not only reduce the mortality and misery of dialysis patients, but will also result in significant reduction in the cost of providing viable health care," says Gura.

The Wearable Artificial Kidney is successful in preliminary tests, including two studies in dialysis patients. The new study provides important information on the technical details that made these promising results possible.

"However, the long-term effect of this technology on the well-being of dialysis patients must be demonstrated in much-needed clinical trials," adds Gura. "Although successful, this is but one additional step on a long road still ahead of us to bring about a much-needed change in the lives of this population."

Other authors were Alexandra S. Macy, Masoud Beizai, and Carlos Ezon (Xcorporeal, Inc); and Thomas A. Golper, MD (Vanderbilt University Medical Center). Dr. Gura receives a salary from Xcorporeal, Inc.

Additionally, significant contributions to the development of this new device were made by Hans Dietrich Polaschegg, PhD, Andrew Davenport, MD, Claudio Ronco MD, Andre Kaplan, MD, and Eli Friedman, MD.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Technical Breakthroughs in the Wearable Artificial Kidney (WAK). Clinical Journal of the American Society of Nephrology, August 20, 2009 DOI: 10.2215/CJN.02790409

Cite This Page:

American Society of Nephrology. "Hello Wearable Kidney, Goodbye Dialysis Machine." ScienceDaily. ScienceDaily, 21 August 2009. <www.sciencedaily.com/releases/2009/08/090820175853.htm>.
American Society of Nephrology. (2009, August 21). Hello Wearable Kidney, Goodbye Dialysis Machine. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/08/090820175853.htm
American Society of Nephrology. "Hello Wearable Kidney, Goodbye Dialysis Machine." ScienceDaily. www.sciencedaily.com/releases/2009/08/090820175853.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins